By using DiabetesTimes.co.uk, you agree to our terms and use of cookies to enhance your experience.
The deadline to enter this year’s Quality in Care (QiC) Diabetes Awards which celebrates innovative practice in diabetes management is looming. Those who wish to submit an entry have until ...
Sanofi’s new insulin and GLP-1 combination Suliqua has received marketing approval from the European Commission. The once-daily treatment combines Lantus (insulin glargine) and with Lyxumia ...
Hinchingbrooke Hospital has won a prestigious national award for raising awareness of a complication of diabetes. The hospital has been presented with the Excellence Award for its management of a ...
Negative emotions are jeopardising people managing their type 2 diabetes, according to new research. A quarter of people who use insulin to manage their condition feel anxious or fearful about ...
Innovation in diabetes care was showcased at the sixth annual QiC Diabetes awards. People working in the diabetes community were praised at the awards ceremony, which took place at Sanofi’s ...
A woman who had a hypo and passed out while driving on a motorway with her baby in the car was safely forced off the road by the police. PC Daniel Pattison responded to reports of a Peugeot ...
A combination of insulin glargine and lixisenatide helps people with type 2 diabetes reach meal-time blood sugar targets better, according to a new study. The LixiLan-L trial investigated a ...
Tarja Stenvall is the general manager for the Diabetes and Cardiovascular Business Unit and UK Country Chair for Sanofi. The pharmaceutical company has an 85-year commitment to improving the ...
A combination insulin/GLP-1 agonist drug has shown greater efficacy in controlling type 2 diabetes. The results of the Sanofi drug iGlarLixi, formerly known as LixiLan, were unveiled at ...
Teams who have “improved services and outcomes” for people with diabetes have just one week to enter the Quality in Care Diabetes (QiC) awards. The programme recognises, rewards and ...